Collaborations
Collaborations

As part of our commitment to advancing human health, we participate in strategic collaborations with academic and commercial partners that are complementary to our expertise in chelation chemistry and synthesis. These partnerships are always win/win undertakings with the goal of providing better service to our clients, producing new intellectual property, and publication of important scientific data in high impact journals.


Some of our valued collaborators are:

  • MDS Nordion – New ligands for radiopharmaceutical applications – MDS Nordion and Macrocyclics Inc. have entered into a research and development collaboration to develop innovative, bifunctional chelates for use in molecular imaging and targeted therapeutic pharmaceuticals in 2005. The collaboration is ongoing and has resulted in the discovery of several new ligands systems that are expected to accelerate the development of Cu-64 and Ga-68 PET imaging applications.

  • Goodwin BiotechPartnering in the development of customer projects that include GMP conjugation – A common denominator for many customers who are undertaking clinical development programs in nuclear medicine with biotargeted agents is the necessity of combining chelation chemistry and bioconjugation chemistry to create a product. For this reason Goodwin Biotech and Macrocyclics have worked on a number of joint customer projects which benefited from the critical strengths of each company: Goodwin Biotechnology, Inc. is a fully integrated cGMP contract manufacturing organization (CMO) of monoclonal antibodies and recombinant proteins for preclinical and clinical trials, and Macrocyclics, Inc., a manufacturer of customized chelating agents, is dedicated to leading-edge development of new chelation chemistry platforms critical for advancement of diagnostic and therapeutic medicine. Each company frequently receives inquiries regarding the possibility of performing complete in-house GMP services for both of these critical components. To this end Goodwin Biotech and Macrocyclics will formally utilize this positive synergy to help our customers achieve their goals in the most efficient manner.

  • VU University – Development of new bifunctional ligands for PET imaging with Zr-89 – Macrocyclics and researchers at VU have been working on new bifunctional ligands designed specifically for the long-lived PET isotope Zr-89.

  • Yale University – Development of multifunctional MRI contrast agents for molecular imaging – Researchers at Yale and Macrocyclics are working together on research proposal aimed at developing a new family of MRI contrast agents that monitor multiple physiological events simultaneously.

  • Washington University – Nanoparticle Based Imaging Platforms